BlackRock, Inc. 13D and 13G filings for Mersana Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 9,205,182 8.000% | 1,360,900 (+17.35%) | Filing |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,844,282 6.500% | 352,353 (+4.70%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,491,929 7.500% | 12,700 (+0.17%) | Filing |
| 2022-01-27 5:13 pm Unchanged | 2021-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,479,229 10.400% | 0 (Unchanged) | Filing |
| 2022-01-26 09:17 am Sale | 2021-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,479,229 10.400% | -508,583 (-6.37%) | Filing |
| 2021-01-26 6:52 pm Purchase | 2020-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,987,812 11.700% | 850,072 (+11.91%) | Filing |
| 2020-07-10 10:39 am Purchase | 2020-06-30 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 7,137,740 10.700% | 4,672,421 (+189.53%) | Filing |
| 2020-02-07 08:45 am Purchase | 2019-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | BlackRock Inc. BLK | 2,465,319 5.100% | 2,465,319 (New Position) | Filing |